10026-13-8Relevant articles and documents
MANUFACTURING METHOD OF FLUOROSULFONYLALKYL VINYL ETHER CHLORIDE
-
Paragraph 0051, (2017/06/13)
PROBLEM TO BE SOLVED: To provide a method for easily controlling generation of hydrochloric acid gas in a method of manufacturing fluorosulfonylalkyl vinyl ether chloride represented by CF2=CFOCF2CF2SO2Cl by using phosphorus pentachloride. SOLUTION: There is provided a manufacturing method of a fluorosulfonylalkyl vinyl ether chloride compound represented by CF2=CFOCF2CF2SO2Cl, including a process of preparing a solution where phosphorus pentachloride is dissolved in phosphorus trichloride and/or a solvent (excluding phosphorus trichloride) and a process of mixing the solution and vinyl ether represented by the general formula::CF2=CFOCF2CF2SO3M, where M is H or an alkali metal atom and reacting the phosphorus pentachloride and the vinyl ether. SELECTED DRAWING: Figure 1 COPYRIGHT: (C)2017,JPOandINPIT
Heterocyclic dihydropyrimidine compounds
-
, (2008/06/13)
Novel heterocyclic dihydropyrimidine compounds useful as inhibitors of potassium channel function (especially inhibitors of the Kv1 subfamily of voltage gated K+ channels, especially inhibitors Kv1.5 which has been linked to the ultra-rapidly activating delayed rectifier K+ current IKur), methods of using such compounds in the prevention and treatment of arrhythmia and IKur-associated conditions, and pharmaceutical compositions containing such compounds.
Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction
-
, (2008/06/13)
Compounds of the formulae (IA) and (IB): wherein R1is C1to C3alkyl optionally substituted with phenyl, Het or a N-linked heterocyclic group selected from piperidinyl and morpholinyl; wherein said phenyl group is optionally substituted by one or more substitutents selected from C1to C4alkoxy; halo; CN; CF3; OCF3or C1to C4alkyl wherein said C1to C4alkyl group is optionally substituted by C1to C4haloalkyl or haloalkoxy either of which is substituted by one or more halo atoms; R2is C1to C6alkyl and R13is OR3or NR5R6, or pharmaceutically or veterinarily acceptable salts thereof, or pharmaceutically or veterinarily acceptable solvates of either entity are potent and selective inhibitors of type 5 cyclic guanosine 3′,5′-monophosphate phosphodiesterase (cGMP PDE5) and have utility in the treatment of, inter alia, male erectile dysfunction (MED) and female sexual dysfunction (FSD).
Muscarinic receptor agonists
-
, (2008/06/13)
This invention relates to a novel class of partial or full muscarinic receptor agonists intermediates for their preparation, and pharmaceutical compositions and methods of use for the treatment or prevention of diseases the treatment or prevention of whic
Synthesis and crystal structure of (PCl4)[Re2Cl9]
Baranov,Khvorykh,Troyanov
, p. 1240 - 1242 (2008/10/08)
The reaction between PCl3 and ReCl5 yielded at 200 °C the ionic tetrachlorophosphonium dirhenium nonachloride, (PCl4)[Re2Cl9]. Single crystal X-ray diffraction analysis revealed a monoclinic unit cell: a = 8.616(3) A?, b = 10.449(4) A?, c = 9.397(3) A?, β= 99.72(3)°, V = 833.9(5) A?3, Z = 2, sp. gr. P21/m, wR2 = 0.1083 and R1 = 0.0527. The ionic compound is built from tetrahedra PCl4+ and face-sharing bioctahedra Re2Cl9-. The Re-Re distance, 2.724 A?, indicates the presence of direct Re-Re interaction.
Polycyclic aromatic azacyclic compounds useful in dyeing
-
, (2008/06/13)
Heterocyclic compounds of the formula STR1 with the substituent meanings given in the description, and derivatives thereof are suitable for dyeing and pigmenting the most diverse substrates.
Imidazole analogs of mevalonolactone and derivatives thereof for use in inhibiting cholesterol biosynthesis and lowering blood cholesterol level
-
, (2008/06/13)
Compounds of the formula STR1 and the pharmaceutically acceptable acid addition salts thereof, wherein the various substituents are defined hereinbelow and the use thereof for inhibiting cholesterol biosynthesis and lowering the blood cholesterol level and, therefore, in the treatment of hyperlipoproteinemia and atherosclerosis, pharmaceutical compositions comprising such compounds and processes for and intermediates in the synthesis of such compounds.
1,4-dihydropyridines
-
, (2008/06/13)
This invention provides compounds useful for treating coronary insufficiency, hypertension, angina pectoris, cardiac arrythmia, heart attack or coronary vasospasm and represented by the general formula: STR1 R1 and R2 are each independently selected from the group consisting of lower alkyl, N-alkylphthalimido and derivatives of N-alkylphthalimido, wherein said N-alkyl group comprises at least 2 carbon atoms; A is a straight or branched chain hydrocarbon moiety containing from 1 to 12 carbon atoms and from 0 to 2 double bonds; R3 is selected from the group of radicals consisting of hydrogen, --NH2 and --NCS; R4 is an aryl or heteroaryl radical; and R5 is a lower alkyl radical or A--R3 ; provided that when R3 is a hydrogen radical at least one of R1 and R2 is not lower alkyl, including both pure enantiomers as well as mixtures thereof; and pharmaceutically-acceptable salts thereof.
Preparation of a phosphorus complex
-
, (2008/06/13)
An improved process for preparing a phosphorus complex of the formula: wherein R is selected from the group consisting of: aryl; substituted aryl, wherein the substituent can comprise at least one member selected from the group consisting of nitro, chloro
